Finance ForgeBETA
Crear cuenta gratis
1)Empresas2)Rankings3)Iniciar sesión
Finance Forge Terminal v1.49.5
PrivacidadTérminosCookiesAviso Legal
● Connected
ZBH US Equity
ZIMMER BIOMET HOLDINGS, INC.
89.14USD▲ 0.29%
Healthcare
Medical Devices
96)Comparar97)Tesis →
Market Cap
$17.0B
Shares Outstanding
191M
EV/EBITDA
10.7×
— Annual —FY2025
Revenue
$8.2B
Gross Margin
69.7%
Operating Margin
13.3%
Net Margin
8.6%
FCF Margin
17.9%
ROE
5.5%
ROCE
5.3%
Net Debt/EBITDA
2.9×
Current Ratio
1.98
D/E Ratio
0.55
Dividend Yield
1.1%
FCF / Share
7.72
Book Value / Share
66.57
ZBH US Equity
89.14USD▲ 0.29%
Tesis →

ZIMMER BIOMET HOLDINGS, INC. (ZBH): análisis fundamental y valoración

ZIMMER BIOMET HOLDINGS, INC. cotiza a 89.14 USD y tiene una capitalización bursátil de $17.0B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud

Price History
Loading...
Perfil
BolsaNYSEPaísUnited StatesEmpleados17,000Beta0.47Web↗ www.zimmerbiomet.com

Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, an…

Múltiplos de Valoración
P/E (Annual)
24.1×
P/E (TTM)
—
P/FCF (Annual)
11.6×
P/FCF (TTM)
—
EV/EBITDA
10.7×
EV/Revenue
2.8×
P/Sales
2.1×
P/Book
1.3×
Rentabilidad (Último Anual)
Gross Margin
69.7%
Operating Margin
13.3%
Net Margin
8.6%
FCF Margin
17.9%
ROE
5.5%
ROCE
5.3%
ROA
3.0%
Effective Tax Rate
15.1%
Métricas TTM
Revenue TTM
—
Gross Profit TTM
—
Operating Income TTM
—
Net Income TTM
—
FCF TTM
—
EPS TTM
—
Quarters Used
—
TTM Period
—
Solidez del Balance
Net Debt
$6.3B
Net Debt / EBITDA
2.9×
Debt / Equity
0.55
Current Ratio
1.98
Interest Coverage
—
Working Capital
$2.5B
Book Value / Share
66.57
Net Debt / Share
33.24
Crecimiento (YoY)
Revenue YoY
+7.2%
Net Income YoY
-22.0%
FCF YoY
+13.7%
EPS Diluted YoY
-19.9%
Retorno al Accionista
Dividend Yield
1.1%
Payout Ratio
27.0%
FCF / Share
7.72
CapEx % Revenue
2.7%
Rev / Employee
484,205
Próximos Eventos
Ex-Dividendo
2026-09-30
Pago Dividendo
2026-10-30
Historial EPS
Periodo2026-112026-082026-042026-02
Real—$2.07$2.09$2.42
Estimado$1.88$2.01$1.86$2.40
Sorpresa—+3.0%+12.4%+0.8%
Empresas similares
Smart Money
vs Sector: Healthcare (1130 empresas)
MétricaZBHMediana SectorΔ
Gross Margin69.7%57.0%+12.7%
Operating Margin13.3%-38.6%+52.0%
Net Margin8.6%-33.6%+42.1%
FCF Margin17.9%-13.9%+31.8%
ROE5.5%-40.4%+45.9%
ROA3.0%-32.0%+35.1%
Current Ratio1.982.84-0.86
Debt / Equity0.550.28+0.27
Scoring Fundamental
Piotroski F-Score
5/ 9Moderado
✓F1ROA positivo (rentabilidad activos)
✓F2Flujo caja operativo positivo
✗F3ROA mejora vs año anterior
✓F4Calidad de beneficios (OCF > ROA)
✗F5Apalancamiento baja
✓F6Liquidez mejora (current ratio)
✓F7Sin dilución accionarial
✗F8Margen bruto mejora
✗F9Rotación activos mejora
Altman Z-ScoreZona Gris
2.33
x1_working_capital0.110
x2_retained_earnings0.503
x3_ebit0.048
x4_market_equity1.637
x5_sales0.356
>2.99 segura · 1.81–2.99 gris · <1.81 riesgo
Capital Allocation
6/ 8Sólida
✓FCF+Free cash flow positivo
✓FCFmMargen FCF > 10%
✓DilucSin dilución significativa (< 2%/año en 3 años)
✓Rev↑Revenue CAGR 3 años > 5%
✗ROCERetorno sobre capital empleado > 10%
✓DeudaDeuda neta/EBITDA < 3× (o posición de caja neta)
✗Mg↑Margen operativo ≥ hace 2-3 años (tolerancia -2pp)
✓Inv.R&D + Capex > 3% de revenue (reinversión en el negocio)
Histórico Piotroski F-Score
Histórico de Múltiplos